Transgene

High-Risk Clinical Trials And Rising Costs Will Delay Returns Yet Unlock Value

AnalystLowTarget

Not Invested

Community Contributor

Published

14 Aug 25

AnalystLowTarget's Fair Value

€1.40

10.0% undervalued

04 Sep

€1.26

8.1%

14.0%

8.1%

14.0%

You can edit this narrative until Aug 14 10:17 PM. Then, changes will post as Updates.

Author's Valuation

€1.410.0% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

€1.4

10.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

34.60%

Biotech revenue growth rate

9.08%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.33%

Calculation

€632.50k

Earnings '28

347.79x

PE Ratio '28

€219.98m

Market Cap '28

€219.98m

Market Cap '28

131.93m

No. shares '28

€1.67

Share Price '28

€1.67 Share Price '28

Discounted to 2025 @ 5.98% p.a.

€1.40

Fair Value '25